Sentences with phrase «share prices change on»

Share prices change on a daily basis and new earnings figures are released every three months.

Not exact matches

But recent market turmoil reminded the world that share prices don't always go up, as rising interest rates, sweeping technological change, and the possibility of a trade war stoked anxiety on Main Street and Wall Street.

In the opinion of the Company's management, adjusted book value per share is useful in an analysis of a property casualty company's book value per share as it removes the effect of changing prices on invested assets (i.e., net unrealized investment gains (losses), net of tax), which do not have an equivalent impact on unpaid claims and claim adjustment expense reserves.

Nedlands - based Proteomics International Laboratories has made a solid debut on the ASX today, closing 2.5 cents above its issue price at 22.5 cents per share, with about 1.13 million shares changing hands.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These risks and uncertainties include competition and other economic conditions including fragmentation of the media landscape and competition from other media alternatives; changes in advertising demand, circulation levels and audience shares; the Company's ability to develop and grow its online businesses; the Company's reliance on revenue from printing and distributing third - party publications; changes in newsprint prices; macroeconomic trends and conditions; the Company's ability to adapt to technological changes; the Company's ability to realize benefits or synergies from acquisitions or divestitures or to operate its businesses effectively following acquisitions or divestitures; the Company's success in implementing expense mitigation efforts; the Company's reliance on third - party vendors for various services; adverse results from litigation, governmental investigations or tax - related proceedings or audits; the Company's ability to attract and retain employees; the Company's ability to satisfy pension and other postretirement employee benefit obligations; changes in accounting standards; the effect of labor strikes, lockouts and labor negotiations; regulatory and judicial rulings; the Company's indebtedness and ability to comply with debt covenants applicable to its debt facilities; the Company's ability to satisfy future capital and liquidity requirements; the Company's ability to access the credit and capital markets at the times and in the amounts needed and on acceptable terms; and other events beyond the Company's control that may result in unexpected adverse operating results.

It is unclear whether the holding caused his company marketing difficulties, or whether his shares changed names, but according to Fisher's most recent posting, he's still bullish on the company (share price prediction up 99 %).

The return an investor receives on his or her share of a home would depend on the home's value change according to its house - specific index rather than the selling price of the home.

Allergan Plc's chief executive on Monday said he was opposed to fundamental changes to the drug company's business strategy, even as its board considers drastic moves like splitting the company, selling off assets or doing deals to turn around a steep drop in its share price.

creation of additional shares of Series C convertible preferred stock; or (iii) effect a change of control, liquidation, dissolution, or winding up of the Company in which the holders of Series C convertible preferred stock would receive an amount per share less than the original issue price plus any declared but unpaid dividends on such shares of Series C convertible preferred stock.

Important factors that may affect the Company's business and operations and that may cause actual results to differ materially from those in the forward - looking statements include, but are not limited to, increased competition; the Company's ability to maintain, extend and expand its reputation and brand image; the Company's ability to differentiate its products from other brands; the consolidation of retail customers; the Company's ability to predict, identify and interpret changes in consumer preferences and demand; the Company's ability to drive revenue growth in its key product categories, increase its market share, or add products; an impairment of the carrying value of goodwill or other indefinite - lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company's management team or other key personnel; the Company's inability to realize the anticipated benefits from the Company's cost savings initiatives; changes in relationships with significant customers and suppliers; execution of the Company's international expansion strategy; changes in laws and regulations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; failure to successfully integrate the Company; the Company's ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the nations in which the Company operates; the volatility of capital markets; increased pension, labor and people - related expenses; volatility in the market value of all or a portion of the derivatives that the Company uses; exchange rate fluctuations; disruptions in information technology networks and systems; the Company's inability to protect intellectual property rights; impacts of natural events in the locations in which the Company or its customers, suppliers or regulators operate; the Company's indebtedness and ability to pay such indebtedness; the Company's dividend payments on its Series A Preferred Stock; tax law changes or interpretations; pricing actions; and other factors.

The share price of Natural Resources, a company with a going concern warning in its financial reports, has risen by over 3,000 % since the company announced its intention of entering the digital currency realm and changing its name to Blockchain Holdings in a report sent to the TASE on October 17.

Net losses on securities of $ 4.3 million this year primarily reflect active risk management in view of macroeconomic conditions and changes in the pricing and liquidity of the Canadian preferred share market.

The Services / Technology table presents 10 of the leading mining services and technology companies on the ASX, listing the latest market cap, and one - day, one - week and one - year percentage change in share prices.

Dec 28 Indian shares were little changed on Thursday ahead of expiry of derivatives contracts and on lingering concerns over government borrowing exceeding target, but metals stocks such as Vedanta Ltd rose tracking global commodity prices.

On the eve of Prime Minister Malcolm Turnbull's arrival in China, Australia's biggest vitamin and dairy companies are desperately seeking clarification over regulatory changes that have smashed their share prices.

Saputo is offering $ 9.00 per Warrnambool share, but under changes to its bid made on December 17, that price will increase to as much as $ 9.60 as its stake in the company increases.

After arbitrators ruled in favor of the Players Union on its collusion grievances from those two offseasons, though, MLB owners changed the way they were colluding: An information - sharing bank was instituted so owners could know what the other owners were negotiating with which free agents, which would help keep free - agent prices down since no team would accidentally blow away the competition with any offer.

Among them is the sequence of time intervals on a stock exchange when there is a change in share prices, which does not happen uniformly.

It examines the reasons for choosing different business forms and then the reasons for changing them (including sole traders, LTD and PLCs, mutuals and the public sector); the role of shareholders and their reasons for investment (including market capitalisation, dividends and ordinary shares); the key influences on share prices and why these are important for a company; and finally the effect of ownership on mission, objectives, decisions and performance.

Click or tap on a number in the gray bar at the bottom of the illustration to see the typical relationship between the average maturity of a bond fund's holdings and its income and share - price variability in a period of changing interest rates.

The price of a fund's shares and the cash flows you receive will depend on the bond market's fluctuations — which are influenced by changes in interest rates — and, of course, the manager's skill.

Brokers who trade on the NYSE will sell and buy shares of AT&T to each other, thereby setting a price for that stock which can change every time shares exchange hands.

Equities risk: includes the risk that changes in share prices will negatively impact on the value of investment.

The current dividend yield is based on the current share price and will change if the share price changes.

The Fund's performance may not match or correlate to that of its Index, either on a daily or aggregate basis due to factors such as Fund expenses, imperfect correlation, rounding of share prices, changes to the composition of the Index, regulatory policies, high portfolio turnover and the use of leverage (if any).

The biggest change is that both institutional and municipal money market funds must move from a stable $ 1.00 price per share to a floating net asset value based on the underlying investments on a daily basis.

1000 shares traded yields $ 36 to $ 86 net gain on $ 0.05 to $ 0.10 stock price change.

In terms of market caps, which is the total valuation of companies based on their current share price and the total number of outstanding stocks, your allocation should rarely change at all.

Since the book value of stocks doesn't change that often (because it represents the price the company sold it for, not the current value on the stock market, and would therefore only change when there were new share issues), almost all changes in total assets or in total liabilities are reflected in Retained Earnings.

The Funds share price may change daily based on the value of its security holdings.

Secondary - market transactions occur at, above or below the ETF indicative NAV at market prices that change throughout the day, based on the supply and demand of Fund shares and on changes in the prices of the Fund's portfolio holdings (see Indicative Value).

This group treats reinvested dividends as a new purchase, thus increasing the cost basis and changing the cost per share and YoC (these could be higher or lower depending on the purchase price).

The major changes since my 2012 valuation have been the revaluation of the Handy & Harman share price, the ModusLink investment and my revaluation of the value of the Webank subsidiary based on the last two years of operating results.

The methodology that I used for the March share spinoff, i.e. taking the dollar change between the closing share price of TTT on March 30th and the opening price on March 31st, dividing by the closing price on March 30th and using that percentage of my TTT (old KHD) cost basis as the new cost basis for the KHDHF shares, does not work for my purposes for the June spinoff; the cost basis works out to something like $ 1.52 using this methodology.

Share prices vary throughout the day, based mainly on the changing intraday value of the underlying assets in the fund.

Sometimes you buy shares when prices are up, and sometimes you buy shares when prices are down, but regular purchases on an automatic investment plan do not react to changing prices.

As equity funds invest in stocks, any change in share prices will have a corresponding impact on the Net Asset Value (NAV) of the fund.

As you pointed out, MRVC's sales are > $ 500M ($ 538M in 2008 according to recent 10K filing); at $ 147M market cap, Value Investors for Change stands to reap quite a profit (depending on when they invested, of course) if the current share price goes to just $ 2 / sh.

As foreign exchanges can be open on days when shares in an iShares fund are not priced, the value of the securities in an iShares fund's portfolio may change on days when shareholders will not be able to purchase or sell an iShares fund's shares.

The Fund's share price may change daily based on the value of its security holdings.

29 - Jul - 12: Sold off half my Livermore Investments (LIV: LN) holding — no particular change in view, mostly just returning back down to a 3.2 % stake (similar to my original / cumulative stake)-- with the share price now at GBP 26.75 p, a 91 % increase on my Baker's Dozen price of GBP 14p helps too..!

On the other hand, management's now upped the potential tender amount to # 35 million (at 150p per share) vs. the # 20 million commitment originally announced in Rasmala's final results in April (which, bizarrely, prompted zero change in the 100 - 105p share price at the time!?).

(10) Total return was calculated by dividing the net change in the share price, during the year, plus the dividends paid per share, during the year, by the closing share price on December 31 or the last trading day of the preceding year

Being a dividend investor has two major advantages, first of all, you do not rely that much on the changes of the share price and when the stock price is on a very low level you just collect the dividends.

Because the Funds may invest in underlying ETFs that hold portfolio securities primarily listed on foreign exchanges, and these exchanges may trade on weekends or other days when the underlying ETFs do not price their shares, the value of some of a Fund's portfolio securities may change on days when you may not be able to buy or sell Fund shares.

I prefer to focus instead on looking at all my positions afresh every day / week, and asking what % holding (if any) should I now own based on the company's business / financial risk, its share price action, its potential fair value upside, the changing micro and macro risk environment, and the relative value of other holdings / buy list stocks.

On a more positive note: A few days ago the CEO apparently changed his compensation for the year from cash to shares (priced as of june 25th).

The options on the bought - out company will change to options on the buyer stock at the same strike price, but for a different number of shares.